AOD-9604 vs 5-Amino-1MQ
Compare the research profiles of AOD-9604 and 5-Amino-1MQ. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesAOD-9604
AOD-9604 (Anti-Obesity Drug)
weight-loss
Phase 2 Clinical Trials (discontinued)
not-approved
5-Amino-1MQ
5-Amino-1-Methylquinolinium
metabolic
Preclinical
not-approved
Detailed Comparison
| Aspect | AOD-9604 | 5-Amino-1MQ |
|---|---|---|
| Overview | A fragment of human growth hormone (amino acids 177-191) marketed specifically for fat burning without affecting blood sugar or causing GH-related side effects. Now banned from compounding by FDA.... | A small molecule peptide gaining traction for targeting visceral fat and activating NAD+ levels to boost metabolic rate. Works by inhibiting NNMT enzyme.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics the fat-burning effects of growth hormone without affecting blood sugar or cell proliferation. Stimulates lipolysis (fat breakdown) and inhibit... | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that when overexpressed leads to fat accumulation. Blocking NNMT increases NAD+ levels and... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.